Weishi China participated in Hainan Free Trade Port Global Special Drug Insurance Media Conference and visited the Lecheng Advance Zone.

Guide: The company in China is affiliated with Thesa, a company based in Tokyo, Japan, a multinational company based in Tokyo, Japan, which is a multinational company based in research and development of pharmaceutical products.
recently, Weishi (China) Investment Co., Ltd. (hereinafter referred to as "Weishi China") was invited to participate in the Hainan Free Trade Port Global Special Drug Insurance Media Conference held in Boao Lecheng International Medical Tourism Advance Zone, Weishi Global Senior Vice President, Weishi China President Feng Yanhui online for the media launch to send a blessing and expressed that Weishi China will strongly support the construction of Hainan Free Trade Port, support the development of Boao City. Li Yunlong, minister of the Department of
's China Access Management Department, visited lecity advance area the day before the media conference.
Lecheng Leading District Authority Party Secretary, Director Gu Gang, Lecheng Medical Supervision Bureau Director Han Hui, Deputy Director Li Lijing and so on participated in the study. Li Yunlong, minister of the Ministry of China Access Management of
, said that The Company has invested in China for nearly 30 years, after learning about the licensing policy of Lecheng Advance Zone, Weishi China immediately took action, has now declared three products into the Lecheng Advance Zone, which will benefit more Chinese patients, so that Chinese patients and patients in other parts of the world have equal treatment opportunities.
has already done a comprehensive understanding and specific planning in access, patient services, approval and other links, and will continue to promote the product in the landing application of Lecheng.
Lecheng Leading District Authority Party Secretary, Director Gu Gang also said that very much look forward to the three products already declared in China, the future can bring more innovative drugs to Lecheng, benefiting the vast number of domestic patients.
Ofseis is affiliated with Seshi Corporation in China, a multinational company based in Tokyo, Japan, which is a multinational company that focuses on research and development of pharmaceutical products.
Weishi China has grown smoothly since entering the Chinese market in the early 1990s.
currently has a total registered capital of $108.54 million.
has formed a field of neuroscience, oncology (special drugs) field, digestive liver disease as the focus area, expand the field of generic drugs, as many as dozens of drugs sold in China's development scale.
.